Roth Capital Downgrades ENTEROMEDICS INC COM to Neutral with Price Target $0.50

Brokerage firm Roth Capital Downgrades its rating on ENTEROMEDICS INC COM(NASDAQ:ETRM). In a research note issued to the investors, the brokerage major Lowers the price-target to $0.50 per share. The shares have been rated Neutral. Previously, the analysts had a Buy rating on the shares. The rating by Roth Capital was issued on Jun 9, 2016.

ENTEROMEDICS INC COM (ETRM) made into the market gainers list on Wednesdays trading session with the shares advancing 6.88% or 0.0251 points. Due to strong positive momentum, the stock ended at $0.3901, which is also near the day’s high of $0.3902. The stock began the session at $0.37 and the volume stood at 1,09,304 shares. The 52-week high of the shares is $17.399913 and the 52 week low is $0.358. The company has a current market capitalization of $3.6 M and it has 92,54,451 shares in outstanding.

ENTEROMEDICS INC COM(ETRM) last announced its earnings results on May 5, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $72.00K. Analysts had an estimated revenue of $150.00K. Earnings per share were $-0.94. Analysts had estimated an EPS of $-0.80.

Several Insider Transactions has been reported to the SEC. On Jun 6, 2016, Peter M. Delange (SVP, Ops & Bus Dev) purchased 20,000 shares at $0.55 per share price.Also, On May 18, 2016, Dan W Gladney (CEO) purchased 84,745 shares at $0.72 per share price.On Nov 16, 2015, Mark B Knudson (CEO) purchased 310,000 shares at $0.16 per share price, according to the Form-4 filing with the securities and exchange commission.

EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology which is referred to as VBLOC therapy is designed to intermittently block the vagus nerve using high frequency low energy electrical impulses. The Company’s initial product is the Maestro System which uses VBLOC therapy to affect metabolic regulatory control limits the expansion of the stomach help control hunger sensations between meals reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company has approvals to commercially launch its product the Maestro Rechargeable System in the United States Australia the European Economic Area and other countries.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

ENTEROMEDICS INC COM - Is it time to Sell?

Top Brokerage Firms are advising their investors on ENTEROMEDICS INC COM. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.